Methotrexate (MTX) is used as an anchor disease-modifying anti-rheumatic drugs
(DMARDs) in treating rheumatoid arthritis (RA) because of its potent efficacy and tolerability …

In rheumatoid arthritis (RA), disease activity cannot be measured in all individual patients
according to a single variable. The Disease Activity Score (DAS) and the DAS28 have been …

Background The Disease Activity Index for Psoriatic Arthritis (DAPSA) is a valid and
discriminative tool. Definitions of disease activity states and therapeutic response are still …

Background Many patients with rheumatoid arthritis (RA) report symptom relief from certain
foods. Earlier research indicates positive effects of food and food components on clinical …

Background Tofacitinib (CP-690,550) is a novel oral Janus kinase inhibitor that is being
investigated as a targeted immunomodulator and disease-modifying therapy for rheumatoid …

Background Methotrexate is the most frequently used first-line antirheumatic drug. We report
the findings of a phase 3 study of monotherapy with tofacitinib, an oral Janus kinase …

In this article, the 2010 European League against Rheumatism (EULAR) recommendations
for the management of rheumatoid arthritis (RA) with synthetic and biological disease …

Objectives To assess predictive factors for rheumatoid arthritis interstitial lung disease (RA-
ILD) in two early rheumatoid arthritis (RA) inception cohorts with a focus on methotrexate …

Objectives To investigate baricitinib (LY3009104, formerly INCB028050), a novel, oral
inhibitor of JAK1/JAK2 in patients with moderate to severe rheumatoid arthritis (RA) despite …

Patient-reported outcomes (PROs) reflect the patient's perspective and are used in
rheumatoid arthritis (RA) routine clinical practice. Patient global assessment (PGA) is one of …